|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1996-6-18
|
|
pubmed:abstractText |
To analyze the safety and efficacy of a short course of granulocyte colony-stimulating factor (G-CSF) to maintain dose-intensity of subsequent cycles of chemotherapy after a prior episode of prolonged neutropenia, without febrile complications, in patients receiving adjuvant treatment for breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AlbanellJJ,
pubmed-author:BaselgaJJ,
pubmed-author:BellmuntJJ,
pubmed-author:BermejoBB,
pubmed-author:CarullaJJ,
pubmed-author:ErelAA,
pubmed-author:GallardoEE,
pubmed-author:RibasAA,
pubmed-author:Solé-CalvoL ALA,
pubmed-author:VeraRR,
pubmed-author:VidalRR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1573-80
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8622074-Adult,
pubmed-meshheading:8622074-Aged,
pubmed-meshheading:8622074-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8622074-Breast Neoplasms,
pubmed-meshheading:8622074-Breast Neoplasms, Male,
pubmed-meshheading:8622074-Chemotherapy, Adjuvant,
pubmed-meshheading:8622074-Cyclophosphamide,
pubmed-meshheading:8622074-Doxorubicin,
pubmed-meshheading:8622074-Female,
pubmed-meshheading:8622074-Fluorouracil,
pubmed-meshheading:8622074-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:8622074-Humans,
pubmed-meshheading:8622074-Leukocyte Count,
pubmed-meshheading:8622074-Male,
pubmed-meshheading:8622074-Methotrexate,
pubmed-meshheading:8622074-Middle Aged,
pubmed-meshheading:8622074-Neutropenia,
pubmed-meshheading:8622074-Safety
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
|
|
pubmed:affiliation |
Medical Oncology Section, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
